title: Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA).
abstract: The literature contains a substantial amount of information about factors that adversely influence the linear growth in up to 85% of patients undergoing haematopoietic SCT (HSCT) with TBI and/or cranial irradiation (CI) for acute leukaemia (AL). By contrast, only a few studies have evaluated the impact of growth hormone (GH) therapy on growth rate and final height (FH) in these children. We evaluated growth rates during the pre- and post-transplant periods to FH in a group of 25 children treated with HSCT (n=22), TBI (n=21) or/and CI (n=8) for AL and receiving GH therapy. At the start of GH treatment, the median height Z-score was -2.19 (-3.95 to 0.02), significantly lower than at AL diagnosis (P<0.001). Overall height gain from start of GH treatment to FH was 0.59Z (-2.72 to 2.93) with a median height Z-score at FH of -1.35 (-5.35 to 0.27). This overall height gain effect was greater in girls than in boys (P=0.04). The number of children with heights in the reference population range was greater after than before GH therapy (P=0.07). At FH the GVHD and GH treatments lasting <2 years were associated with shorter FH (P=0.02 and 0.05). We found a measurable beneficial effect of GH treatment on growth up to FH.
authors: CHU Clermont-Ferrand, Centre Régional de Cancérologie et Thérapie Cellulaire Pédiatrique, Hôpital Estaing, Clermont-Ferrand, France.
authors: F
authors: F
authors: Isfan
authors: J
authors: J
authors: Kanold
authors: E
authors: E
authors: Merlin
authors: A
authors: A
authors: Contet
authors: N
authors: N
authors: Sirvent
authors: E
authors: E
authors: Rochette
authors: M
authors: M
authors: Poiree
authors: D
authors: D
authors: Terral
authors: H
authors: H
authors: Carla-Malpuech
authors: R
authors: R
authors: Reynaud
authors: B
authors: B
authors: Pereira
authors: P
authors: P
authors: Chastagner
authors: M C
authors: MC
authors: Simeoni
authors: P
authors: P
authors: Auquier
authors: G
authors: G
authors: Michel
authors: F
authors: F
authors: Deméocq
mesh_terms: D001827:Body Height / Q000187:drug effects* / Q000528:radiation effects*; D002648:Child; D002675:Child, Preschool; D016371:Cranial Irradiation / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D019382:Human Growth Hormone / Q000008:administration & dosage* / Q000172:deficiency; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D012189:Retrospective Studies; D014916:Whole-Body Irradiation / Q000009:adverse effects*
chemical_list: D019382:Human Growth Hormone